A new cancer treatment that shows promise in halting tumor growth in one-third of patients has been developed. The treatment, which works by blocking a protein that fuels cancer cells, has been hailed as a “game-changer” by researchers.
What is this new cancer treatment?
The new cancer treatment, known as AMG 510, is the first drug to target a specific cancer gene known as KRAS. KRAS is a gene that has been found to be mutated in many types of cancer, including lung, pancreatic, and colorectal cancer.
The mutated form of KRAS is essentially “stuck on,” and it orders cells to divide and take up nutrients even when they don’t need to. This fuels the growth and spread of cancer cells.
Until now, KRAS has been considered “undruggable” because of the shape of the protein it produces.
However, AMG 510 is designed to fit into the shape of the mutated KRAS protein, blocking its ability to order cells to divide and take up nutrients. This effectively halts tumor growth.
How effective is AMG 510?
According to the results of a clinical trial, AMG 510 was effective in halting tumor growth in one-third of patients with advanced non-small cell lung cancer.
The trial involved 129 patients who had tried at least two other treatments but did not respond, and whose tumor cells had mutations in the KRAS gene. Of the 129 patients, 23 responded to AMG 510 and saw their tumors shrink or stop growing.
While the response rate may seem low, it is important to note that this is the first drug to target KRAS, which has long been considered “undruggable.” The fact that it is effective in one-third of patients with advanced non-small cell lung cancer is a significant breakthrough. It is also worth noting that the clinical trial is ongoing, and more patients may respond to AMG 510 in the future.
What are the side effects of AMG 510?
In the clinical trial, the most common side effects of AMG 510 were diarrhea, fatigue, and nausea. However, these side effects were mostly mild or moderate in severity.
Related Article
Cutting-edge cancer therapy stops tumor development in 33% of cases
One patient experienced a more serious side effect, known as pleural effusion (fluid buildup around the lungs), but this was deemed unrelated to the drug.
It is worth noting that AMG 510 is still being tested in clinical trials, and further research is needed to determine its long-term safety and efficacy.
However, the early results are promising, and researchers are excited about the potential of this new cancer treatment.
What does this mean for cancer treatment?
The development of AMG 510 is a significant breakthrough in cancer treatment.
It is the first drug to target the KRAS gene, which has long been considered “undruggable.” The fact that it is effective in halting tumor growth in one-third of patients with advanced non-small cell lung cancer is a major milestone.
The success of AMG 510 could lead to the development of other drugs that target KRAS and other “undruggable” cancer genes. This could open up new avenues for cancer treatment and improve the prognosis for people with cancer.
Conclusion
The development of AMG 510 is a significant breakthrough in cancer treatment.
It is the first drug to target the KRAS gene, which has long been considered “undruggable.” The fact that it is effective in halting tumor growth in one-third of patients with advanced non-small cell lung cancer is a major milestone. While AMG 510 is still being tested in clinical trials, researchers are excited about its potential and the possibilities it could open up for cancer treatment.
